Mersana rises after peer Immunogen's ovarian cancer drug shows positive results

ImmunoGen

03/05/2023 16:08

** Shares of Mersana Therapeutics  MRSN.O  rise ~40% to
$6.12, among top pct. gainers across U.S. exchanges
    ** Stock set for biggest one-day pct. rise in over eight
months, if gains hold
    ** Peer Immunogen Inc's  IMGN.O  ovarian cancer drug shows
that it helps to extend lives of patients in late-stage trial
    ** IMGN plans to submit marketing application in Europe and
supplemental application in U.S. for conversion to regular
approval in H2 this year
    ** The drug candidate, Elahere, had been given accelerated
approval by the FDA 
    ** MRSN is testing its drug, UpRi, to treat a type of
ovarian cancer currently in late stage trials
    ** MRSN stock up ~5% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))